Get the Stockscreener App
26.27
0.42%
-0.11
Pre-market:
26.06
-0.21
-0.80%
Arcutis Biotherapeutics Inc stock is traded at $26.27, with a volume of 2.14M.
It is down -0.42% in the last 24 hours and up +6.01% over the past month.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
See More
Previous Close:
$26.38
Open:
$26.22
24h Volume:
2.14M
Relative Volume:
1.02
Market Cap:
$3.30B
Revenue:
$415.62M
Net Income/Loss:
$-2.38M
P/E Ratio:
-925.00
EPS:
-0.0284
Net Cash Flow:
$16.92M
1W Performance:
-0.72%
1M Performance:
+6.01%
6M Performance:
+20.34%
1Y Performance:
+51.85%
1-Day Range:
$25.19
$26.68
1-Week Range:
$25.13
$28.29
52-Week Range:
$16.57
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
26.27 | 3.30B | 415.62M | -2.38M | 16.92M | -0.0284 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Trading Systems Reacting to (ARQT) Volatility - Stock Traders Daily
Arcutis Biotherapeutics, Inc. (ARQT) Stock Forecasts - Yahoo! Finance Canada
Arcutis Biotherapeutics (ARQT) Stock Analysis: A 42.53% Potential Upside Ignites Investor Interest - DirectorsTalk Interviews
Arcutis Biotherapeutics (NASDAQ:ARQT): Affordable Growth With Strong Upside Potential - ChartMill
Arcutis Biotherapeutics, Inc.(NasdaqGS: ARQT) added to S&P 1000 - marketscreener.com
Arcutis Biotherapeutics, Inc.(NasdaqGS: ARQT) added to S&P 600 Health Care - marketscreener.com
Arcutis Biotherapeutics, Inc.(NasdaqGS: ARQT) added to S&P Composite 1500 - marketscreener.com
Arcutis Biotherapeutics, Inc.(NasdaqGS: ARQT) added to S&P 600 - marketscreener.com
Arcutis Biotherapeutics Inc. (ARQT) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Arcutis Biotherapeutics (ARQT) Insider Masaru Matsuda Sells 3,67 - GuruFocus
Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares - Investing.com
Arcutis Biotherapeutics EVP Masaru Matsuda Sells 3,674 Shares Under 10b5-1 Plan - kalkinemedia.com
Arcutis Biotherapeutics EVP Matsuda sells $91.8k in shares By Investing.com - Investing.com UK
Arcutis Biotherapeutics director Welgus sells $114k in shares By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics (ARQT) Moves 11.2% Higher: Will This Strength Last? - Yahoo Finance
Here’s What Arcutis’ CEO Said at the Morgan Stanley Healthcare Conference That Made the Stock Jump 11% - TIKR.com
Former Arcutis (NASDAQ: ARQT) officer plans multimillion-dollar stock sale - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) director plans $114K stock sale - Stock Titan
The Technical Signals Behind (ARQT) That Institutions Follow - Stock Traders Daily
Arcutis EVP, Chief Legal Officer Masaru Matsuda sells 9,989 shares for $249,861 - Bitget
Arcutis Biotherapeutics (ARQT) Insider Masaru Matsuda Sells 9,98 - GuruFocus
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock By Investing.com - Investing.com India
Arcutis Biotherapeutics EVP Masaru Matsuda sells $249,985 stock - Investing.com
Arcutis (ARQT) officer lines up Rule 144 stock sale - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals - ChartMill
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Atopic Dermatitis Drugs Market Set to Reach USD 33.42 Billion by 2035, at a CAGR of 7.70% - GlobeNewswire Inc.
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
(ARQT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
ARQT Stock Price, Quote & News - Syfe
Arcutis director Terrie Curran sells $956k in shares By Investing.com - Investing.com Nigeria
Arcutis director Terrie Curran sells $956k in shares - Investing.com
Here's Why You Should Add ARQT Stock to Your Portfolio Now - theglobeandmail.com
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Insider Decision Unfolding At Arcutis Biotherapeutics: Terrie Curran Exercises Options, Resulting In $18K - benzinga.com
Arcutis Biotherapeutics Director Terrie Curran Executes Stock Option and Sells Shares on August 20, 2026 - Kalkine Media
Arcutis Biotherapeutics CMO Patrick Burnett Sells Shares to Cover Tax Withholding on RSU Vesting - Kalkine Media
Tejara Capital Ltd Buys Shares of 113,084 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Roflumilast Cream 0.3% Approved for Plaque Psoriasis in Children as Young as 2 - Pharmacy Times
Polar Capital Holdings Plc Buys Arcutis Biotherapeutics Inc (ARQ - GuruFocus
Arcutis (NASDAQ: ARQT) director to sell 1,072 shares - Stock Titan
ARQT Looks 18.5% Undervalued on GF Value™ After Health Canada Ap - GuruFocus
PrZORYVE® Cream 0.05% Receives Health Canada Approval for Children Aged 2 to 5 Years with Mild to Moderate Atopic Dermatitis - PR Newswire Canada
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 4,730 Shares - MarketBeat
Arcutis (NASDAQ: ARQT) officer to sell 1,697 shares after recent August trades - Stock Titan
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup - ChartMill
Arcutis (ARQT) Q2 2026 Earnings: EPS Beats Its Estimate in Latest Trading; Shares After the Report: The Stock Ends Up 3.63% at the CloseSegment Revenue Breakdown - Vinanet
Arcutis (NASDAQ: ARQT) holder plans $123,834 August sale - Stock Titan
Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action? - webull.com
Arcutis (ARQT) Q2 2026 Earnings Call Transcript - AOL.com
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):